Cell Communication and SignalingImmunologyPeer-reviewed journal article
Immunosuppressants Rewire the Gut Microbiome-Alloimmune Axis Through Time-Dependent and Tissue-Specific Mechanisms
Long WuiD, Allison KensiskiiD, Samuel J. GavzyiD, Yang SongiD, Hnin Wai Lwin, Michael FranceiD, Dejun Kong, Lushen LiiD, Ram Lakhan, Vikas SaxenaiD, Wenji PiaoiD, Marina Willson ShirkeyiD, Valeria R. MasiD, Brendan James Lohmar, Yan ShuiD, Jonathan S. BrombergiD, Bing MaiD
Abstract
BackgroundLifelong immunosuppressive therapy is required to prevent allograft rejection in organ transplantation. Current immunosuppressants effectively suppress adaptive and innate immune responses, but their broad, antigen-non-specific effects often result in severe off-target complications. It remains a significant unmet medical need in transplant medicine. ResultsIn this study we investigated immunosuppressant effects of four major immunosuppressant classes, including tacrolimus, prednisone, mycophenolate mofetil (MMF), and fingolimod (FTY), on the gut microbiome, metabolic pathways, lymphoid architecture and lymphocyte trafficking after up to 30-day chronic exposure. Despite their distinct mechanisms of action and not designed to target the gut, all immunosuppressive drugs induced profound and time-dependent alterations in both intestine gene expression and gut microbiome composition. Progressive alterations from moderate early, drug-specific changes to a strikingly convergent microbial dysbiosis, marked by significant expansion of pathobionts of Muribaculaceae, occurred across all drug classes. Concurrently, all drugs uniformly induced significant suppression of mucosal immunity including B cell, immunoglobulin, and antigen recognition. Time-dependent changes in lymph node (LN) reorganization and cellular composition were also observed, marked by a progressive shift toward pro-inflammatory phenotypes in gut-draining mesenteric LNs and a gradual loss of tolerogenic architecture in peripheral LNs. Drug-specific metabolic alterations and distinct phases of intestinal transcriptional responses were also characterized. Notably, MMF and FTY demonstrated the most robust immunomodulatory properties, and were able to suppress alloantigen-induced inflammation through mediating regulatory T cell distribution and LN remodeling. ConclusionsTogether, these findings highlight the underappreciated complexity and temporal dynamics immunosuppressants effects, particularly their impact on the gut and compartmentalized regulation of alloimmune in lymphoid tissues. Understanding these relationships offers new opportunities for refining immunosuppressive strategies to reduce treatment-related off-target complications and improve long-term organ transplant outcomes.
- organism: human
- assay: metagenomics
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 3
- FWCI
- 0.90
- Field percentile
- top 27%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome
Long Wu, Allison Kensiski, … Jonathan S. Bromberg·JCI InsightPeer-reviewed·Apr 21, 2025
- Unraveling interindividual differences and functional consequences of gut microbial metabolism of immunosuppressants
Maral Baghai Arassi, Nicolai Karcher, … Michael Zimmermann·bioRxiv·Mar 28, 2024
- Mycophenolate mofetil increases susceptibility toopportunistic fungal infection independent of lymphocytes
Rory H. Gibson, Robert J Evans, … Simon A. Johnston·bioRxiv·Sep 19, 2018
- A short course of Tofacitinib sustains the immunoregulatory effect of CTLA4-Ig in presence of inflammatory cytokines and promotes long-term survival of murine cardiac allografts
M. Iglesias, S. Khalifian, … G. Raimondi·bioRxiv·Nov 18, 2020
- Early immunomodulatory program triggered by pro-tolerogenic Bifidobacterium pseudolongum drives cardiac transplant outcomes
S. J. Gavzy, A. Kensiski, … J. S. Bromberg·bioRxiv·Oct 13, 2022
- Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites
Y. Guo, C. M. Crnkovic, … H. Jeong·bioRxiv·Oct 1, 2018